Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v2.4.0.8
Commitments and Contingencies - Additional Information (Detail) (USD $)
9 Months Ended 12 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Commitment And Contingencies [Line Items]      
Gross proceeds from private placement of common stock $ 3,939,800 $ 11,913,442 $ 13,000,000
Convertible Promissory Note [Member]
     
Commitment And Contingencies [Line Items]      
convertible promissory note issued to pay technology access fee 1,956,000    
Maturity date of convertible note Dec. 31, 2013    
MU1140 [Member]
     
Commitment And Contingencies [Line Items]      
License Agreement, Original Date Jun. 22, 2000    
License agreement, first amendment date Sep. 15, 2000    
License agreement, second amendment date Jul. 10, 2002    
License agreement, third amendment date Sep. 25, 2002    
License agreement, fourth amendment date Mar. 17, 2003    
License agreement date fifth amended Apr. 19, 2013    
Patents license expiration period 2017 through 2019    
Smart Replacement Therapy [Member]
     
Commitment And Contingencies [Line Items]      
License Agreement, Original Date Aug. 04, 1998    
License agreement, first amendment date Sep. 15, 2000    
License agreement, second amendment date Jul. 10, 2002    
License agreement, third amendment date Sep. 25, 2002    
License agreement, fourth amendment date Mar. 17, 2003    
License agreement date fifth amended Apr. 19, 2013    
Patent right filling date Jun. 07, 1995    
Patent effective date Mar. 04, 1997    
Patent right expire date Jun. 07, 2015    
UFRF License Agreements [Member]
     
Commitment And Contingencies [Line Items]      
Company's obligation to pay from percentage of selling price of product 5.00%    
Company's obligation to pay from all revenue received from sublicenses 22.00%    
One-time commercialization fee would be due on the first anniversary of first commercial sale 5,000    
Post-commercialization minimum royalty payments 50,000    
One-time additional royalty payment would be due when total cumulative royalties 2,000,000    
Total royalties due to UFRF 10.00%    
Minimum annual maintenance payment per license agreement 10,000    
Aggregate minimum annual maintenance payment 20,000    
Quarterly maintenance payment to UFRF under installment plan 5,000    
Lantibiotic ECC [Member]
     
Commitment And Contingencies [Line Items]      
License Agreement, Original Date Jun. 05, 2012    
Termination notice period 90 days    
Common stock issued 4,392,425    
Percentage company pay on quarterly basis out of gross profit 25.00%    
Company's obligation to make payment from all revenue received from sublicensing 50.00%    
Period during which company cannot terminate license agreement voluntarily 18 months    
Period during which company cannot terminate license agreement 12 months    
Maximum percentage of primary investment securities to investment of shares issued 10.00%    
Lantibiotic ECC [Member] | Investigational New Drug Application [Member]
     
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares 1.00%    
Lantibiotic ECC [Member] | Clinical Study Phase 2 [Member]
     
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares 1.50%    
Lantibiotic ECC [Member] | Clinical Study Phase 3 [Member]
     
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares 2.00%    
Lantibiotic ECC [Member] | Filing of First Investigational New Drug Application [Member]
     
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares 2.50%    
Lantibiotic ECC [Member] | First Regulatory Approval of Oragenics Product [Member]
     
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares 3.00%    
Probiotics ECC [Member]
     
Commitment And Contingencies [Line Items]      
License Agreement, Original Date Sep. 30, 2013    
Percent of company pay out of net sales 10.00%    
Termination notice period 90 days    
Maximum period to cure the breach 60 days    
Up-front technology access fee 6,000,000    
Milestone amount payable one 2,000,000    
Milestone amount payable two 5,000,000    
Milestone amount payable three 10,000,000    
Milestone measurement period 30 days    
Probiotics ECC [Member] | Intrexon [Member]
     
Commitment And Contingencies [Line Items]      
Common stock issued 1,348,000    
Company's common stock shares sold 1,300,000    
Per shares price $ 3.00    
Gross proceeds from private placement of common stock 3,900,000    
Probiotics ECC [Member] | Convertible Promissory Note [Member]
     
Commitment And Contingencies [Line Items]      
convertible promissory note issued to pay technology access fee $ 1,956,000    
Maturity date of convertible note Dec. 31, 2013